The fact that AhR intersects with multiple oncogenic signaling pathways suggests that the activation of AhR may offer therapeutic vulnerability in cancer cells where individual pathway components are not easily targeted or ‘druggable’ (e.g., c-MYC). This evidence concerns the gene AHR and cancer.